Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Neurotoxicol Teratol. 2015 Jun 12;52(0 0):162–169. doi: 10.1016/j.ntt.2015.06.003

Figure 5.

Figure 5

In vivo exposure to HBCDD does not affect the expression of GABAergic or glutamatergic markers in the striatum. Animals received either 0 (control) or 25 mg/kg HBCDD for 30 days and were then evaluated for alterations to (A) GAT1, (B) vGAT, and (C) vGlut in the striatum. (D) Representative immunoblot bands for each marker. Data represents mean ± SEM (4 control and 6 HBCDD treated animals per experimental group).